These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. [Hepatocellular carcinoma - correlation between signal intensity on MRI and degree of differentiation?]. Kessing R Rofo; 2013 Oct; 185(10):928. PubMed ID: 24490251 [No Abstract] [Full Text] [Related]
27. [Hepatocellular carcinoma - is there a sequential genesis?]. Weiß J Rofo; 2013 Jun; 185(6):525. PubMed ID: 23740706 [No Abstract] [Full Text] [Related]
28. [Hyperintense hepatocellular carcinoma in MRI - clinical and pathologic features]. Lichert F Rofo; 2013 Jul; 185(7):605-6. PubMed ID: 23804127 [No Abstract] [Full Text] [Related]
29. Hepatobiliary contrast agents in MR: Where we stand and future perspectives. Rimola J; Forner A Liver Int; 2021 May; 41(5):888-890. PubMed ID: 33861894 [No Abstract] [Full Text] [Related]
30. Education and Imaging. Hepatobiliary and pancreatic: spontaneous regression of hepatocellular cancer demonstrated by contrast-enhanced ultrasonography. Nishijima N; Marusawa H; Kita R; Osaki Y; Chiba T J Gastroenterol Hepatol; 2009 Jun; 24(6):1153. PubMed ID: 19638097 [No Abstract] [Full Text] [Related]
31. Hepatocellular carcinoma exhibiting a concentric structure of different histologic grades: evaluation by chondroitin sulfate iron colloid-enhanced MR imaging. Kamba M; Suto Y; Kodama F; Ohta Y; Kobayashi J; Horie Y; Kawasaki H J Magn Reson Imaging; 1996; 6(2):406-8. PubMed ID: 8859586 [TBL] [Abstract][Full Text] [Related]
32. The Global Reading Room: Imaging Detection of Hepatocellular Carcinoma. Chernyak V; van der Pol CB; Vernuccio F; Yoshimitsu K AJR Am J Roentgenol; 2022 May; 218(5):922-923. PubMed ID: 34643109 [No Abstract] [Full Text] [Related]
33. Improving Postsurgical Outcome in Patients with HCC by Using a Hepatobiliary Contrast Agent. Motosugi U Radiology; 2019 Dec; 293(3):605-606. PubMed ID: 31596183 [No Abstract] [Full Text] [Related]
34. Spontaneous regression of hepatocellular carcinoma: potential promise for the future. Vardhana HG; Panda M South Med J; 2007 Feb; 100(2):223-4. PubMed ID: 17330700 [No Abstract] [Full Text] [Related]
35. Case 206: persistent hypertrophic primary vitreous. Li CD; Meltzer DE Radiology; 2014 Jun; 271(3):921-5. PubMed ID: 24848962 [TBL] [Abstract][Full Text] [Related]
36. T2-shortening effect of fibrinogen inclusions on MRI of hepatocellular carcinoma: case report and experimental relaxation measurement. Fujita M; Horinouchi T; Ishiguro S; Ishihara R; Kasugai H; Yamada T; Sasaki Y; Maeda H; Inoue E; Kuroda C AJR Am J Roentgenol; 2004 Feb; 182(2):459-62. PubMed ID: 14736681 [No Abstract] [Full Text] [Related]
37. Non-invasive prediction of microvascular invasion in patients with hepatocellular carcinoma: is there any added value in combining imaging features and radiomics? Dioguardi Burgio M Eur Radiol; 2023 Sep; 33(9):6459-6461. PubMed ID: 37391622 [No Abstract] [Full Text] [Related]
38. Diagnosis of hepatocellular carcinoma: Which MRI contrast agent? Which diagnostic criteria? Kim SY Clin Mol Hepatol; 2020 Jul; 26(3):309-311. PubMed ID: 32536046 [No Abstract] [Full Text] [Related]